Thromboembolic Disease In Surgery For Malignancy-Rationale For Prolonged Thromboprophylaxis

ABSTRACT

Patients undergoing surgery for malignancy are at increased risk of initial and recurrent venous thromboembolism (VTE). Several factors have been found to increase the risk of deep vein thrombosis (DVT) in cancer patients both during the first days after the operation and after discharge from hospital. Although, in general, thromboprophylaxis is provided to cancer patients after surgery, the length of time these patients require prophylaxis has not yet been established. Autopsy series, clinical series, and clinical trials indicate that up to about 40% of VTE occurs post discharge. General surgical patients undergoing major abdominal surgery require VTE prophylaxis, and prolonged thromboprophylaxis should be considered in the post-discharge period in high-risk patients, particularly those with cancer. Evidence from studies in general and orthopedic surgery show that prolonged prophylaxis reduces the number of thromboembolic events after discharge from hospital. Prophylaxis should be simple, safe, and effective and should be administered easily to allow continuation of therapy after discharge. Low-molecular-weight heparins are potentially the most suitable agents for long-term thromboprophylaxis in cancer patients.

KEYWORD

Thromboprophylaxis - deep-vein thrombosis - pulmonary embolism - low-molecular-weight heparin (LMWH) - cancer surgery

REFERENCES

• 1 Geerts W H, Heit J A, Clagett G P. Prevention of venous thromboembolism.  Chest . 2001;  119 132S-175S
• 2 ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment.  Br J Surg . 1997;  84 1099-1103
• 3 Nicolaides A N, Bergqvist D, Hull R. Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence).  Int Angiol . 1997;  16 3-38
• 4 Cohen A T, Edmondson R A, Phillips M J, Ward V P, Kakkar V V. The changing pattern of venous thromboembolic disease.  Haemostasis . 1996;  26 65-71
• 5 Rasmussen M S, Wille-Jørgensen P, Jørgensen L N. Postoperative fatal pulmonary embolism in a general surgical department.  Am J Surg . 1995;  169 214-216
• 6 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk.  Arch Surg . 1992;  127 310-313
• 7 Robinson K S, Anderson D R, Gross M. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial.  Ann Intern Med . 1997;  127 439-445
• 8 Planes A, Vochelle N, Darmon J Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo.  Lancet . 1996;  348 224-228
• 9 Bergqvist D, Benoni G, Björgell O. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.  N Engl J Med . 1996;  335 696-700
• 10 Dahl O E, Andreassen G, Aspelin T. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin).  Thromb Haemost . 1997;  77 26-31
• 11 Lassen M R, Borris L C, Anderson B S. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) Study.  Thromb Res . 1998;  89 281-287
• 12 Hull R D, Pineo G F, Francis C. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.  Arch Intern Med . 2000;  160 2208-2215
• 13 Heit J A, Elliott C G, Trowbridge A A. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med . 2000;  132 853-861
• 14 Lausen I, Jensen R, Jørgensen L N. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis.  Eur J Surg . 1998;  164 657-663
• 15 Bergqvist D, Agnelli G, Cohen A T. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.  N Engl J Med . 2002;  346 975-980
• 16 Donati M B. Cancer and thrombosis.  Haemostasis . 1994;  24 128-131
• 17 Sproul E E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis.  Am J Cancer . 1938;  34 566-585
• 18 Ambrus J L, Ambrus C M, Pickern J, Soldes S, Bross I. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis.  J Med . 1975;  6 433-458
• 19 Kakkar A K, Williamson R C. Prevention of venous thromboembolism in cancer patients.  Semin Thromb Hemost . 1999;  25 239-243
• 20 Carson J L, Kelley M A, Duff A. The clinical course of pulmonary embolism.  N Engl J Med . 1992;  326 1240-1245
• 21 Gore J M, Appelbaum J S, Greene H L, Dexter L, Dalen J E. Occult cancer in patients with acute pulmonary embolism.  Ann Intern Med . 1982;  96 556-560
• 22 Prandoni P, Lensing A W, Büller H R. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.  N Engl J Med . 1992;  327 1128-1133
• 23 Griffin M R, Stanson A W, Brown M L. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms.  Arch Intern Med . 1987;  147 1907-1911
• 24 Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study.  BMJ . 1994;  308 891-894
• 25 Baron J A, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer.  Lancet . 1998;  351 1077-1080
• 26 Sørensen H T, Mellemkjaer L, Steffensen F H, Olsen J H, Nielsen G L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.  N Engl J Med . 1998;  338 1169-1173
• 27 Goldberg R J, Seneff M, Gore J M. Occult malignant neoplasm in patients with deep venous thrombosis.  Arch Intern Med . 1987;  147 251-253
• 28 Trousseau A. Lectures on Clinical Medicine.  London: The New Syndenham Society 1872: 282-332
• 29 Virchow R. Phlogose und Thrombose im GefäBsystem. In: Virchow R, ed. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin Frankfurt, Germany: von Meidinger Sohn 1856: 458
• 30 Moore Jr D F, Osteen R T, Karp D D, Steele Jr G, Wilson R E. Anticoagulants, venous thromboembolism, and the cancer patient.  Arch Surg . 1981;  116 405-407
• 31 Levine M N, Gent M, Hirsh J. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.  N Engl J Med . 1988;  318 404-407
• 32 Ogawa S, Gerlach H, Esposito C. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties.  J Clin Invest . 1990;  85 1090-1098
• 33 Patterson W P, Ringenberg Q S. The pathophysiology of thrombosis in cancer.  Semin Oncol . 1990;  17 140-146
• 34 Rickles F R, Edwards R L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited.  Blood . 1983;  62 14-31
• 35 Booth B W, Weiss R B. Venous thrombosis during adjuvant chemotherapy (Letter).  N Engl J Med . 1981;  305 170
• 36 Weiss R B, Tormey D C, Holland J F, Weinberg V E. Venous thrombosis during multimodal treatment of primary breast carcinoma.  Cancer Treat Rep . 1981;  65 677-679
• 37 Goodnough L T, Saito H, Manni A, Jones P K, Pearson O H. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients.  Cancer . 1984;  54 1264-1268
• 38 Donati M B, Semeraro N. Cancer cell procoagulants and their pharmacological modulation.  Haemostasis . 1984;  14 422-429
• 39 Reich R, Thompson E W, Iwamoto Y. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.  Cancer Res . 1988;  48 3307-3312
• 40 Carty N J, Taylor I, Roath O S, el-Baruni K, Francis J L. Tissue procoagulant activity may be important in sustaining metastatic tumour growth.  Clin Exp Metastasis . 1992;  10 175-181
• 41 Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients.  Br J Surg . 1985;  72 105-108
• 42 Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988.  Br J Surg . 1991;  78 849-852
• 43 Clarke-Pearson D L, Jelovsek F R, Creasman W T. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis.  Obstet Gynecol . 1983;  61 87-94
• 44 Clarke-Pearson D L, Synan I S, Coleman R E, Hinshaw W, Creasman W T. The natural history of postoperative venous thromboemboli in gynecologic oncology: a prospective study of 382 patients.  Am J Obstet Gynecol . 1984;  148 1051-1054
• 45 Sørensen C, Andersen M, Kristiansen V B, Jensen R, Wille-Jørgensen P. The occurrence of late thromboembolic complications after elective abdominal surgery [in Danish].  Ugeskr Laeger . 1990;  152 1586-1587
• 46 Scurr J H, Coleridge-Smith P D, Hasty J H. Deep venous thrombosis: a continuing problem.  BMJ . 1988;  297 28
• 47 Kakkar V V, Corrigan T P, Fossard D P. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial.  Lancet . 1975;  2 45-51
• 48 Kiil J, Kiil J, Axelsen F, Andersen D. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin.  Lancet . 1978;  1 1115-1116
• 49 Clarke-Pearson D L, Coleman R E, Synan I S, Hinshaw W, Creasman W T. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin.  Am J Obstet Gynecol . 1983;  145 606-613
• 50 Wille-Jørgensen P, Kjaergaard J, Thorup J. Heparin with and without dihydroergotamine in prevention of thromboembolic complications of major abdominal surgery. A randomized trial.  Arch Surg . 1983;  118 926-928
• 51 Clarke-Pearson D L, Synan I S, Hinshaw W M, Coleman R E, Creasman W T. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy.  Obstet Gynecol . 1984;  63 92-98
• 52 Bergqvist D, Lindblad B. The thromboprophylactic effect of graded elastic compression stockings in combination with dextran 70.  Arch Surg . 1984;  119 1329-1331
• 53 Wille-Jørgensen P, Thorup J, Fischer A, Holst-Christensen J, Flamsholt R. Heparin with and without graded compression stockings in the prevention of thromboembolic complications of major abdominal surgery: a randomized trial.  Br J Surg . 1985;  72 579-581
• 54 Ockelford P A, Patterson J, Johns A S. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin).  Thromb Haemost . 1989;  62 1046-1049
• 55 Leizorovicz A, Picolet H, Peyrieux J C, Boissel J P. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of logiparin and standard heparin. HBPM Research Group.  Br J Surg . 1991;  78 412-416
• 56 Wille-Jørgensen P, Hauch O, Dimo B. Prophylaxis of deep venous thrombosis after acute abdominal operation.  Surg Gynecol Obstet . 1991;  172 44-48
• 57 Kakkar V V, Cohen A T, Edmonson R A. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group.  Lancet . 1993;  341 259-265
• 58 Collins R, Scrimgeour A, Yusuf S, Phil D, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.  N Engl J Med . 1988;  318 1162-1173
• 59 Skinner J A, Gerrard D J, Zahn H. An assessment of deep venous function following total hip arthroplasty complicated by venographically proven deep vein thrombosis.  Thromb Haemost . 1995;  73 1110
• 60 Prandoni P, Lensing A W, Cogo A. The long-term clinical course of acute deep venous thrombosis.  Ann Intern Med . 1996;  125 1-7
• 61 Andersen M, Wille-Jørgensen P. Late complications of asymptomatic deep venous thrombosis.  Eur J Surg . 1991;  157 527-530
• 62 Cohen A T, Khushal A. Extended thromboprophylaxis following lower limb arthroplasty: what do the clinical trials mean?.  Haemostasis . 2000;  30 88-94
• 63 Mohr D N, Silverstein M D, Murtaugh P A, Harrison J M. Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment.  Arch Intern Med . 1993;  153 2221-2228
• 64 Lieberman J R, Wollaeger J, Dorey F. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty.  J Bone Joint Surg Am . 1997;  79 319-325
• 65 Leclerc J R, Gent M, Hirsh J, Geerts W H, Ginsberg J S. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group.  Arch Intern Med . 1998;  158 873-878
• 66 Cohen A T, Mohamed M S, Kakkar V V. The clinical experience of reviparin in the prevention of deep vein thrombosis.  Drugs Today . 1995;  31 5-9
• 67 Paiement G D, Wessinger S J, Hughes R, Harris W H. Routine use of adjusted low-dose warfarin to prevent venous thromboembolism after total hip replacement.  J Bone Joint Surg Am . 1993;  75 893-898
• 68 Cohen A T, Skinner J A, Kakkar V V. Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?.  BMJ . 1994;  309 1213-1215
• 69 Davies L M, Richardson G A, Cohen A T. Economic evaluation of enoxaparin as post discharge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery.  Value in Health . 2000;  3 397-406
• 70 Detournay B, Planes A, Vochelle N, Fagnani F. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement.  Pharmacoeconomics . 1998;  13 81-89
• 71 Sarasin F P, Bounameaux H. Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery.  Arch Surg . 1996;  131 694-697
• 72 Friedman R J, Dunsworth G A. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty.  Clin Orthop . 2000;  370 171-182